Creative Biolabs Released Modotuximab for Research Use

SHIRLEY, NY - Apr 22, 2020 - April 22, 2020, Creative Biolabs, as a leading supplier in recombinant antibody discovery and manufacturing, is equipped with cutting-edge hybridoma development and phage display platforms to be able to offer customers with high-quality and professional services. Its product lines are from antibody/peptide libraries, Biosimilar cell lines, Chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies. Recently, Creative Biolabs announced the modotuximab to assist researchers in different fields, including academia, industry and clinical trial all over the world. As the technique develops, Creative Biolabs also brings the most advanced biotechnology techniques to develop services and products.

Modotuximab is a kind of recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibition EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types. This product from Creative Biolabs is an ADCC enhanced antibody produced by our Afuco™ platform.  

“this product from Creative Biolabs cost nearly a year to be developed. Scientists from R&D contributes a lot to develop it and attest its performance in different clinical and academic research projects. So it is believed that products offered by Creative Biolabs performance well and assist researchers successful. What’s more, depending on the most advanced technique platform, Creative Biolabs is always providing the high-quality and professional products and services related to recombinant antibody fields. It also has been the notable point in the development history of Creative Biolabs.” said Dr. Abbot, a senior scientist from Creative Biolabs, located in USA.

“among our clients, a majority of customers are loyal to Creative Biolabs, due to its careful service for 24 hours per day. And Creative Biolabs allows customers to directly keep contact with scientists from R&D in Creative Biolabs. They can communicate their problems during their projects. Our scientists will be patient to analyze the troublesome.” said an assistant of Dr. Abbot.

About Creative Biolabs

Since its establishment, Creative Biolabs are dedicated to develop all kinds of recombiant antibody to treat a great range of diseases, such as cancers, infections and etc. A custom-service-centered enterprise is the main goal for all staff in Creative Biolabs. Additionally, this kind of model is very significant to optimize the drug development process. With this motivation, Creative Biolabs trys their best to deliver the highest quality to clients, resulting in accelerating the pace of technology development.